The efficacy of nilotinib treatment approaches in frontline CML
0 Views
administrator
07/08/23
Timothy Hughes, MD, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, shares some insights into a study comparing the use of nilotinib versus a nilotinib plus imatinib switch approach for the frontline treatment of chronic myeloid leukemia (CML). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
-
Category
Show more
Facebook Comments
No comments found